Tissue-type plasminogen activator therapy versus primary coronary angioplasty: Impact on myocardial tissue perfusion and regional function 1 month after uncomplicated myocardial infarction

被引:43
|
作者
Agati, L
Voci, P
Hickle, P
Vizza, DC
Autore, C
Fedele, F
Feinstein, SB
Dagianti, A
机构
[1] Univ Roma La Sapienza, Dept Cardiol & Cardiac Surg, I-00161 Rome, Italy
[2] Univ Illinois, Dept Cardiol, Chicago, IL USA
关键词
D O I
10.1016/S0735-1097(97)00487-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. This study sought to compare the impact of primary coronary angioplasty and thrombolytic therapy for acute myocardial infarction (AMI) on 1-month infarct size and microvascular perfusion. Background. The effect of the reperfusion strategies of primary coronary angioplasty and thrombolytic therapy on microvascular integrity still remains to be determined. Methods. Sixty two consecutive patients with a first AMI, undergoing intravenous tissue-type plasminogen activator (t-PA) therapy (32 patients, Group I) or primary angioplasty (30 patients, Group II), were studied. Only patients with 1-month Thrombolysis in Myocardial Infarction (TIMI) flow grade 2 or 3 were selected for the study, Patients in whom primary angioplasty was unsuccessful or those with clinical evidence of failed reperfusion were excluded. Microvascular perfusion was assessed at 1 month by intracoronary injection of sonicated microbubbles. Contrast score index (CSI) and wall motion score index (WMSI) were derived using qualitative methods. Results. At baseline there were no significant differences between groups for age, risk factors, time to hospital presentation, Killip class on admission, prevalence of multivessel disease or anterior infarct site, infarct area extension before reperfusion, peak creatine kinase levels and postinfarction treatment. Conversely, significant differences between groups were found at follow-up for percent residual infarct related-artery (IRA) stenosis (70 +/- 12 vs 36 +/- 14 [mean +/- SD], p = 0.0001), CSI (1.02 +/- 0.4 vs. 1.49 +/- 0.5, p = 0.0003) and WMSI (1.67 +/- 0.3 vs. 1.45 +/- 0.3, p = 0.015). In particular, in the subset of patients with TIMI grade 3 flow, a perfusion defect occurred in one or more segments subtended by the IRA in 72% of Group I versus 31% of Group II patients (p < 0.00001) and in 27% of Group I versus 8% of Group II segments (p < 0.00001), Conclusions. The present study shows, in a highly selected cohort with successful IRA recanalization, that primary angioplasty is more effective than thrombolysis in preserving microvascular flow and preventing extension of myocardial damage at 1-month after AMI. (C) 1998 by the American College of Cardiology.
引用
收藏
页码:338 / 343
页数:6
相关论文
共 50 条
  • [31] FIBRIN METABOLISM IN PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION DURING AND AFTER TREATMENT WITH TISSUE-TYPE PLASMINOGEN-ACTIVATOR
    RING, ME
    BUTMAN, SM
    BRUCK, DC
    FEINBERG, WM
    CORRIGAN, JJ
    THROMBOSIS AND HAEMOSTASIS, 1988, 60 (03) : 428 - 433
  • [32] PERICARDIAL-EFFUSION AFTER INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR FOR ACUTE MYOCARDIAL-INFARCTION
    BELKIN, RN
    MARK, DB
    ARONSON, L
    SZWED, H
    CALIFF, RM
    KISSLO, J
    AMERICAN JOURNAL OF CARDIOLOGY, 1991, 67 (06): : 496 - 500
  • [33] FINAL REPORT OF A RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND EMERGENCY CORONARY ANGIOPLASTY THERAPY FOR ACUTE MYOCARDIAL-INFARCTION
    TOPOL, EJ
    ONEILL, WW
    LANGBURD, AB
    BATES, ER
    BOURDILLON, PDV
    WALTON, JA
    GRINES, CL
    KLINE, E
    PITT, B
    CIRCULATION, 1986, 74 (04) : 22 - 22
  • [34] MYOCARDIAL TISSUE SALVAGE WITH RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR (RT-PA) FOLLOWING CORONARY THROMBOLYSIS
    FRANGAKIS, CJ
    OLIVER, WR
    BERGER, H
    CIRCULATION, 1986, 74 (04) : 262 - 262
  • [35] EFFECTIVENESS OF MULTIPLE BOLUS ADMINISTRATION OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR IN ACUTE MYOCARDIAL-INFARCTION
    KHAN, MI
    HACKETT, DR
    ANDREOTTI, F
    DAVIES, GJ
    REGAN, T
    HAIDER, AW
    MCFADDEN, E
    HALSON, P
    MASERI, A
    AMERICAN JOURNAL OF CARDIOLOGY, 1990, 65 (16): : 1051 - 1056
  • [36] THROMBOLYTIC TREATMENT OF ACUTE MYOCARDIAL-INFARCTION WITH RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR - CORONARY STATE AFTER 4-WEEKS
    SCHMIDT, WG
    VONESSEN, R
    UEBIS, R
    EFFERT, S
    RUTSCH, W
    SCHARTL, M
    SCHMUTZLER, H
    ERBEL, R
    MEYER, J
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1986, 7 (02) : A16 - A16
  • [37] RANDOMIZED ANGIOGRAPHIC TRIAL OF RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR (ALTEPLASE) IN MYOCARDIAL-INFARCTION
    CARNEY, RJ
    MURPHY, GA
    BRANDT, TR
    DALEY, PJ
    PICKERING, E
    WHITE, HJ
    MCDONOUGH, TJ
    VERMILYA, SK
    TEICHMAN, SL
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1992, 20 (01) : 17 - 23
  • [38] CORONARY THROMBOLYSIS WITH HUMAN TISSUE-TYPE PLASMINOGEN-ACTIVATOR (TD-2061) IN PATIENTS WITH EVOLVING MYOCARDIAL-INFARCTION
    GOTO, Y
    KANEMOTO, N
    HIROSAWA, K
    KIMATA, S
    KAWAI, C
    YUI, Y
    YAMAMOTO, Y
    JAPANESE CIRCULATION JOURNAL-ENGLISH EDITION, 1988, 52 (08): : 736 - 736
  • [39] A RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND EMERGENCY CORONARY ANGIOPLASTY IN PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION
    TOPOL, EJ
    ONEILL, WW
    LANGBURD, AB
    WALTON, JA
    BOURDILLON, PDV
    BATES, ER
    GRINES, CL
    SCHORK, AM
    KLINE, E
    PITT, B
    CIRCULATION, 1987, 75 (02) : 420 - 428
  • [40] RANDOMIZED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL-INFARCTION
    VERSTRAETE, M
    BORY, M
    COLLEN, D
    ERBEL, R
    LENNANE, RJ
    MATHEY, D
    MICHELS, HR
    SCHARTL, M
    UEBIS, R
    BERNARD, R
    BROWER, RW
    DEBONO, DP
    HUHMANN, W
    LUBSEN, J
    MEYER, J
    RUTSCH, W
    SCHMIDT, W
    VONESSEN, R
    LANCET, 1985, 1 (8433): : 842 - 847